Jim Simons Incyte Corp Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Incyte Corp stock. As of the latest transaction made, Renaissance Technologies LLC holds 3,881,932 shares of INCY stock, worth $317 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares

3,881,932

Previous 3,708,732 4.67%

Holding current value

$317 Million

Previous $225 Million 17.72%

% of portfolio

0.37%

Previous 0.36%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$55.17 - $71.22 $9.56 Million - $12.3 Million	173,200 Added 4.67%	3,881,932 $264 Million
Q1 2025 May 14, 2025	SELL	$60.0 - $75.26 $22.6 Million - $28.4 Million	-377,200 Reduced 9.23%	3,708,732 $225 Million
Q4 2024 Feb 13, 2025	SELL	$65.08 - $83.38 $26.9 Million - $34.5 Million	-413,608 Reduced 9.19%	4,085,932 $282 Million
Q3 2024 Nov 13, 2024	SELL	$57.33 - $68.61 $41.2 Million - $49.3 Million	-718,797 Reduced 13.77%	4,499,540 $297 Million
Q2 2024 Aug 09, 2024	SELL	$51.18 - $63.75 $23.4 Million - $29.2 Million	-458,100 Reduced 8.07%	5,218,337 $316 Million
Q1 2024 May 13, 2024	BUY	$56.55 - $66.59 $6.93 Million - $8.16 Million	122,500 Added 2.21%	5,676,437 $323 Million
Q4 2023 Feb 13, 2024	BUY	$52.16 - $64.19 $39.5 Million - $48.6 Million	757,404 Added 15.79%	5,553,937 $349 Million
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $1.83 Million - $2.09 Million	-31,656 Reduced 0.66%	4,796,533 $277 Million
Q2 2023 Aug 11, 2023	SELL	$60.95 - $75.51 $47.2 Million - $58.5 Million	-774,244 Reduced 13.82%	4,828,189 $301 Million
Q1 2023 May 12, 2023	BUY	$70.23 - $86.01 $72.6 Million - $89 Million	1,034,200 Added 22.64%	5,602,433 $405 Million
Q4 2022 Feb 13, 2023	SELL	$67.18 - $84.11 $18.7 Million - $23.5 Million	-279,000 Reduced 5.76%	4,568,233 $367 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $19.6 Million - $24.5 Million	-295,500 Reduced 5.75%	4,847,233 $323 Million
Q2 2022 Aug 12, 2022	BUY	$66.18 - $83.18 $29.5 Million - $37 Million	445,100 Added 9.47%	5,142,733 $391 Million
Q1 2022 May 13, 2022	BUY	$66.02 - $79.71 $7.06 Million - $8.52 Million	106,900 Added 2.33%	4,697,633 $373 Million
Q4 2021 Feb 11, 2022	BUY	$63.34 - $74.11 $11.4 Million - $13.3 Million	179,500 Added 4.07%	4,590,733 $337 Million
Q3 2021 Nov 12, 2021	SELL	$68.67 - $84.02 $7.13 Million - $8.73 Million	-103,900 Reduced 2.3%	4,411,233 $303 Million
Q2 2021 Aug 13, 2021	SELL	$79.87 - $87.53 $30.6 Million - $33.6 Million	-383,600 Reduced 7.83%	4,515,133 $380 Million
Q1 2021 May 13, 2021	SELL	$76.02 - $100.5 $75.3 Million - $99.5 Million	-990,400 Reduced 16.82%	4,898,733 $398 Million
Q4 2020 Feb 10, 2021	SELL	$80.74 - $97.7 $25.5 Million - $30.9 Million	-316,217 Reduced 5.1%	5,889,133 $512 Million
Q3 2020 Nov 13, 2020	SELL	$85.07 - $109.69 $5.61 Million - $7.24 Million	-66,000 Reduced 1.05%	6,205,350 $557 Million
Q2 2020 Aug 13, 2020	BUY	$74.18 - $108.93 $124 Million - $182 Million	1,669,090 Added 36.27%	6,271,350 $652 Million
Q1 2020 May 14, 2020	BUY	$63.18 - $85.97 $63.3 Million - $86.1 Million	1,001,257 Added 27.8%	4,602,260 $337 Million
Q4 2019 Feb 13, 2020	BUY	$73.04 - $95.72 $62.6 Million - $82.1 Million	857,383 Added 31.25%	3,601,003 $314 Million
Q3 2019 Nov 13, 2019	BUY	$72.82 - $86.52 $56.9 Million - $67.6 Million	781,310 Added 39.82%	2,743,620 $204 Million
Q2 2019 Aug 12, 2019	BUY	$73.52 - $88.7 $82.4 Million - $99.5 Million	1,121,310 Added 133.33%	1,962,310 $167 Million
Q1 2019 May 14, 2019	BUY	$63.56 - $88.17 $47.3 Million - $65.7 Million	744,600 Added 772.41%	841,000 $72.3 Million
Q4 2018 Feb 13, 2019	BUY	$58.5 - $69.94 $5.64 Million - $6.74 Million	96,400 New	96,400 $6.13 Million

Others Institutions Holding INCY

# of Institutions

724

Shares Held

203M

Call Options Held

560K

Put Options Held

246K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $18.2B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account